Role of taxanes in the combined modality treatment of patients with locally advanced non-small cell lung cancer

H. Choy, H. Pyo, J. S. Kim, R. MacRae

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

The plant-derived taxanes have a unique mechanism of cytotoxic action and have shown interesting response and survival data in metastatic non-small cell lung cancer (NSCLC). Based on these results, taxane-based regimens have been investigated in combination with radiotherapy in unresectable NSCLC. Trials with paclitaxel-based concurrent chemoradiotherapy have shown 50 -100% tumour response rates, 12 - 26 month median survivals and 32 - 52% 2-year survival rates. Trials with concurrent chemoradiotherapy with docetaxel have shown 35 - 92% tumour response rates, 12 - 23 month median survivals, and 41 - 43% 2 year survival rates. Taxane-based concurrent chemoradiotherapy for stage III NSCLC appears promising. Large ongoing randomised trials will define the role of these agents in the treatment of locally advanced NSCLC.

Original languageEnglish (US)
Pages (from-to)963-974
Number of pages12
JournalExpert Opinion on Pharmacotherapy
Volume2
Issue number6
DOIs
StatePublished - 2001

Fingerprint

Taxoids
Non-Small Cell Lung Carcinoma
Chemoradiotherapy
docetaxel
Survival
Survival Rate
Therapeutics
Paclitaxel
Neoplasms
Radiotherapy
taxane

Keywords

  • Combined modality treatment
  • Docetaxel
  • Lung cancer
  • Paclitaxel
  • Radiotherapy
  • Taxanes

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Role of taxanes in the combined modality treatment of patients with locally advanced non-small cell lung cancer. / Choy, H.; Pyo, H.; Kim, J. S.; MacRae, R.

In: Expert Opinion on Pharmacotherapy, Vol. 2, No. 6, 2001, p. 963-974.

Research output: Contribution to journalArticle

@article{a16f991771f34471868e8dd1b4e28d92,
title = "Role of taxanes in the combined modality treatment of patients with locally advanced non-small cell lung cancer",
abstract = "The plant-derived taxanes have a unique mechanism of cytotoxic action and have shown interesting response and survival data in metastatic non-small cell lung cancer (NSCLC). Based on these results, taxane-based regimens have been investigated in combination with radiotherapy in unresectable NSCLC. Trials with paclitaxel-based concurrent chemoradiotherapy have shown 50 -100{\%} tumour response rates, 12 - 26 month median survivals and 32 - 52{\%} 2-year survival rates. Trials with concurrent chemoradiotherapy with docetaxel have shown 35 - 92{\%} tumour response rates, 12 - 23 month median survivals, and 41 - 43{\%} 2 year survival rates. Taxane-based concurrent chemoradiotherapy for stage III NSCLC appears promising. Large ongoing randomised trials will define the role of these agents in the treatment of locally advanced NSCLC.",
keywords = "Combined modality treatment, Docetaxel, Lung cancer, Paclitaxel, Radiotherapy, Taxanes",
author = "H. Choy and H. Pyo and Kim, {J. S.} and R. MacRae",
year = "2001",
doi = "10.1517/14656566.2.6.963",
language = "English (US)",
volume = "2",
pages = "963--974",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Informa Healthcare",
number = "6",

}

TY - JOUR

T1 - Role of taxanes in the combined modality treatment of patients with locally advanced non-small cell lung cancer

AU - Choy, H.

AU - Pyo, H.

AU - Kim, J. S.

AU - MacRae, R.

PY - 2001

Y1 - 2001

N2 - The plant-derived taxanes have a unique mechanism of cytotoxic action and have shown interesting response and survival data in metastatic non-small cell lung cancer (NSCLC). Based on these results, taxane-based regimens have been investigated in combination with radiotherapy in unresectable NSCLC. Trials with paclitaxel-based concurrent chemoradiotherapy have shown 50 -100% tumour response rates, 12 - 26 month median survivals and 32 - 52% 2-year survival rates. Trials with concurrent chemoradiotherapy with docetaxel have shown 35 - 92% tumour response rates, 12 - 23 month median survivals, and 41 - 43% 2 year survival rates. Taxane-based concurrent chemoradiotherapy for stage III NSCLC appears promising. Large ongoing randomised trials will define the role of these agents in the treatment of locally advanced NSCLC.

AB - The plant-derived taxanes have a unique mechanism of cytotoxic action and have shown interesting response and survival data in metastatic non-small cell lung cancer (NSCLC). Based on these results, taxane-based regimens have been investigated in combination with radiotherapy in unresectable NSCLC. Trials with paclitaxel-based concurrent chemoradiotherapy have shown 50 -100% tumour response rates, 12 - 26 month median survivals and 32 - 52% 2-year survival rates. Trials with concurrent chemoradiotherapy with docetaxel have shown 35 - 92% tumour response rates, 12 - 23 month median survivals, and 41 - 43% 2 year survival rates. Taxane-based concurrent chemoradiotherapy for stage III NSCLC appears promising. Large ongoing randomised trials will define the role of these agents in the treatment of locally advanced NSCLC.

KW - Combined modality treatment

KW - Docetaxel

KW - Lung cancer

KW - Paclitaxel

KW - Radiotherapy

KW - Taxanes

UR - http://www.scopus.com/inward/record.url?scp=0034864647&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034864647&partnerID=8YFLogxK

U2 - 10.1517/14656566.2.6.963

DO - 10.1517/14656566.2.6.963

M3 - Article

VL - 2

SP - 963

EP - 974

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 6

ER -